Loading…
Enliven Therapeutics, Inc. is projected to rise to $67.75 by 2027, a +33% move from its current price of $51.09. ELVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $49.57 | $51.13 | $52.74 | +0.08% |
| Jul 15 | $48.98 | $51.17 | $53.46 | +0.16% |
| Jul 16 | $48.54 | $51.21 | $54.03 | +0.24% |
| Jul 17 | $48.18 | $51.25 | $54.52 | +0.32% |
| Jul 18 | $47.87 | $51.29 | $54.97 | +0.40% |
| Jul 19 | $47.59 | $51.33 | $55.37 | +0.48% |
| Jul 20 | $47.34 | $51.38 | $55.76 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $47.34 | $51.38 | $55.76 | +0.56% |
| Week 2 | $46.02 | $51.66 | $58.00 | +1.12% |
| Week 3 | $45.09 | $51.95 | $59.86 | +1.69% |
| Week 4 | $44.36 | $52.24 | $61.53 | +2.26% |
| Week 5 | $43.75 | $52.54 | $63.08 | +2.83% |
| Week 6 | $43.24 | $52.83 | $64.55 | +3.40% |
| Week 7 | $42.79 | $53.12 | $65.96 | +3.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer.
Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
The company was founded in 2019 and is headquartered in Boulder, Colorado. The asset sits in the Healthcare category.
Enliven Therapeutics, Inc. (ELVN) is currently priced at $50.08 per share and trades with a market capitalization of $3.58B, ranking 1622. The price outlook is guided by a multi-year forecast that shows a path of growth, with 2026 expecting an average price of $50.08 and continuing higher through 2027–2050.
Highlights include 2027 avg $65.47, 2028 avg $89.97, 2029 avg $121.51, 2030 avg $137.42, 2031 avg $141.32, 2032 avg $163.34, 2033 avg $175.64, 2034 avg $207.71, 2035 avg $279.46, 2040 avg $391.86, and 2050 avg $936.90. The forecast also shows a 2050 max of $1,989.65 and a 2026 max of $70.83.
A major floor 47.0% below — a decisive break under it would weaken the trend.
The nearest floor, 34.2% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 25.6% above — clearing it would confirm fresh momentum.
Key ELVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $51.00 | Buy | $50.99 | Buy |
| MA 10 | $50.53 | Buy | $50.06 | Buy |
| MA 20 | $47.90 | Buy | $47.89 | Buy |
| MA 50 | $43.09 | Buy | $44.05 | Buy |
| MA 100 | $39.22 | Buy | $39.55 | Buy |
| MA 200 | $30.34 | Buy | $33.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.07 | Neutral |
| Stoch RSI (14) | 29.36 | Neutral |
| CCI (20) | 75.50 | Neutral |
| Williams %R (14) | -17.52 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 5.12 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 82.48 | Sell |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 7.12 | Buy |
| Ultimate (7,14,28) | 59.49 | Neutral |
| Momentum (10) | 1.97 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 51.72 | Sell |
| ADX (14) | 26.89 | Buy |
| ATR (14) | 1.19 | Info |
The 30-day technical picture is bullish. RSI12 is 70 and market sentiment is BULLISH. The 50-day simple moving average is $42.11 and the 200-day simple moving average is $28.94. Support is seen at $33.63 and resistance at $50.08. The 30-day range spans from a low of $38.93 to a high of $64.42.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.14 | $51.09 | $71.31 | 0% | Neutral | |
| $53.28 | $67.75 | $91.53 | +33% | Bullish | |
| $65.56 | $86.08 | $121.18 | +68% | Bullish | |
| $88.51 | $119.35 | $173.49 | +134% | Bullish | |
| $100.21 | $138.36 | $206.60 | +171% | Bullish | |
| $100.56 | $141.88 | $216.86 | +178% | Bullish | |
| $116.45 | $167.64 | $261.66 | +228% | Bullish | |
| $124.09 | $182.06 | $289.60 | +256% | Bullish | |
| $139.03 | $207.70 | $336.18 | +307% | Bullish | |
| $182.48 | $277.38 | $456.26 | +443% | Bullish | |
| $238.95 | $393.16 | $691.72 | +670% | Bullish | |
| $517.78 | $978.80 | $1,898.33 | +18.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.14 | $51.09 | $61.47 | +0.00% |
| August 2026 | $45.54 | $53.93 | $65.69 | +5.55% |
| September 2026 | $46.03 | $54.94 | $67.78 | +1.88% |
| October 2026 | $44.82 | $53.87 | $67.16 | -1.96% |
| November 2026 | $45.18 | $54.62 | $68.70 | +1.40% |
| December 2026 | $46.27 | $56.24 | $71.31 | +2.96% |
Click any year to see its month-by-month ELVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ELVN is projected to trade between $15.14 and $71.31, averaging $51.09 — a potential gain of 0% from today's $51.09. Price action looks broadly range-bound.
Enliven Therapeutics, Inc.'s 2027 outlook centres on $67.75, within a $53.28 to $91.53 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ELVN could reach as high as $121.18, with a base case around $86.08 and support toward $65.56 — roughly +68% from $51.09. Momentum favours further upside here.
Expect ELVN to range from $88.51 to $173.49 through 2029. The $119.35 average target implies a +134% move from current prices. That is up +39% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ELVN price prediction for 2030 points to an average of $138.36 (low $100.21, high $206.60) — a potential gain of +171% on today's $51.09. Momentum favours further upside here.
In 2031, ELVN is projected to trade between $100.56 and $216.86, averaging $141.88 — a potential gain of +178% from today's $51.09. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Enliven Therapeutics, Inc.'s 2032 outlook centres on $167.64, within a $116.45 to $261.66 range. That is up +18% on the projected 2031 average. That marks a +228% change versus current levels. Momentum favours further upside here.
By 2033, ELVN could reach as high as $289.60, with a base case around $182.06 and support toward $124.09 — roughly +256% from $51.09. Buyers look set to stay in control over this stretch.
Expect ELVN to range from $139.03 to $336.18 through 2034. The $207.70 average target implies a +307% move from current prices. That is up +14% on the projected 2033 average. Momentum favours further upside here.
The ELVN price prediction for 2035 points to an average of $277.38 (low $182.48, high $456.26) — a potential gain of +443% on today's $51.09. Buyers look set to stay in control over this stretch.
In 2040, ELVN is projected to trade between $238.95 and $691.72, averaging $393.16 — a potential gain of +670% from today's $51.09. That is up +42% on the projected 2035 average. Momentum favours further upside here.
Enliven Therapeutics, Inc.'s 2050 outlook centres on $978.80, within a $517.78 to $1,898.33 range. That is up +149% on the projected 2040 average. That marks a +18.2x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELVN today (≈ 19.573302 ELVN) could be worth
$19,158.38
+$18,158.38 (+1816%) by 2050 · US Dollar
Based on the average projected ELVN price of $978.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELVNwould be worth at today's price.
$1,000 invested in ELVN on Jul 10, 2025 (≈ 43.898155 ELVN) would be worth
$2,242.76
+$1,242.76 (+124.3%) today · 2.24× · US Dollar
Based on a ELVN entry price of $22.78 vs. today's $51.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $49.82 | $1,025.49 | +2.5% |
| 1 month ago | $37 | $1,380.81 | +38.1% |
| 3 months ago | $45.32 | $1,127.32 | +12.7% |
| 6 months ago | $25.03 | $2,041.15 | +104.1% |
| 1 year ago | $22.78 | $2,242.76 | +124.3% |
| All time (5.0y) ago | $23.6 | $2,164.83 | +116.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELVN forecast.
Our base-case forecast reaches $100.00 around 2029.
Implied market cap at $100.00: $7.14B
The multi-year forecast depicts a bullish trajectory, with sentiment turning BULLISH from 2027 onward and remaining so through 2050. In 2026 the min is $15.14, the avg is $50.08 and the max is $70.83, with ROI of 0. By 2030 the avg price is forecast at $137.42 and ROI at 174.4, moving higher to $391.86 (ROI 682.5) by 2040 and $936.90 (ROI 1770.8) by 2050, all under a bullish framing.
These figures illustrate substantial upside potential over the long term, alongside the inherent uncertainty of future clinical and market developments. The likely drivers are ongoing clinical programs ELVN-001 and ELVN-002, but these figures remain estimates, not guarantees.
Tap a question to reveal the answer.
2030 min $94.70, avg $137.42, max $216.24; ROI 174.4; sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward, with 2026 neutral. These are estimates and not guarantees.
Yes—the 2050 max is $1,989.65 and the 2050 avg is $936.90, indicating the potential to exceed $1,000 in the high-end scenario.
Current price is $50.08 and market cap is $3.58B.
Sentiment is BULLISH; RSI14 is 70.00; SMA50 is $42.11 and SMA200 is $28.94. Support is $33.63 and resistance is $50.08. The 30-day range is from $38.93 to $64.42.
Enliven Therapeutics, Inc. Community Discussion
0Share your Enliven Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.